Decomposing the Energetic Impact of Drug Resistant Mutations in HIV-1 Protease on Binding DRV

Citations Over TimeTop 10% of 2010 papers

Abstract

Darunavir (DRV) is a high affinity (4.5×10(-12) M, ΔG = -15.2 kcal/mol) HIV-1 protease inhibitor. Two drug-resistant protease variants FLAP+ (L10I, G48V, I54V, V82A) and ACT (V82T, I84V) decrease the binding affinity with DRV by 1.0 kcal/mol and 1.6 kcal/mol respectively. In this study the absolute and relative binding free energies of DRV with wild-type protease, FLAP+ and ACT were calculated with MM-PB/GBSA and thermodynamic integration methods, respectively. Free energy decomposition elucidated that the mutations conferred resistance by distorting the active site of HIV-1 protease so that the residues that lost binding free energy were not limited to the sites of mutation. Specifically the bis-tetrahydrofuranylurethane moiety of DRV maintained interactions with the FLAP+ and ACT variants, whereas the 4 - amino phenyl group lost more binding free energy with the protease in the FLAP+ and ACT complexes than in the wild-type protease which could account for the majority of the loss in binding free energy. This suggested that replacement of the 4 - amino phenyl group might generate new inhibitors less susceptible to the drug resistant mutations.

Related Papers

• → Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir(2015)46 cited
• → Nine Crystal Structures Determine the Substrate Envelope of the MDR HIV-1 Protease(2011)24 cited
• → Models of HIV-1 protease with peptides representing its natural substrates(1998)7 cited
• Investigation of Darunavir resistance against triple mutant (V32I, I47V and V82I) in HIV-1 protease by molecular simulation approach(2013)
• → Using substrate envelope to develop better HIV‐1 protease inhibitors.(2020)